Most people would probably consider $10B a high upper bound for the junior biotech appellation. In any case, my top four picks are: RVNC, ENTA, MNTA, and ADXS. (Also own small positions in OCRX and EGRX.) Among large caps, I like ABT and BMY (especially after the recent ESMO sell-off).
p.s. I have a longstanding position in MON, which is in the process of (maybe) being acquired by Bayer. Bayer itself looks cheap for a major player in both pharma and ag-biotech.
Market Data 
Markets 
AI
